FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin

The FDA granted breakthrough therapy designation to enfortumab vedotin based on results from the dose-escalation cohort and expansion cohort A of the phase Ib/II EV-103 trial.

Source: CancerNetwork - February 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news